SRZNW
Surrozen, Inc. [SRZNW] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
SRZNW Stock Summary
In the News
SRZNW Financial details
Company Rating
Neutral
Market Cap
22.44M
Income
-28.45M
Revenue
12.5M
Book val./share
22.39
Cash/share
21.36
Dividend
-
Dividend %
-
Employees
74
Optionable
No
Shortable
Yes
Earnings
31 Mar 2023
P/E
-9.87
Forward P/E
-
PEG
-5.39
P/S
1.73
P/B
5.75
P/C
0
P/FCF
-0.64
Quick Ratio
6.81
Current Ratio
7.25
Debt / Equity
0.09
LT Debt / Equity
0.03
-
-
EPS (TTM)
-14.14
EPS next Y
-
EPS next Q
-
EPS this Y
78.49%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
9.83%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
14.28%
Inst Trans
1.17%
ROA
-49%
ROE
-44%
ROC
-0.81%
Gross Margin
100%
Oper. Margin
-306%
Profit Margin
-212%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.0323-0.0323
52W High
-
52W Low
-
RSI
49
Rel Volume
-
Avg Volume
-
Volume
155
Perf Week
-39.58%
Perf Month
-29.95%
Perf Quarter
-
Perf Half Y
383.33%
-
-
-
-
Beta
0.742
-
-
Volatility
0%, 0.01%
Prev Close
0%
Price
0.029
Change
0%
SRZNW Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-12-31
| Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0 | 0 | 0 | 5.4 | 0 | |
| Net income per share | -4.13 | -41.01 | -22.48 | -11.95 | -21.33 | |
| Operating cash flow per share | -3.57 | -36.57 | -20.9 | -19.07 | -20 | |
| Free cash flow per share | -3.83 | -37.67 | -21.44 | -19.39 | -20.2 | |
| Cash per share | 4.93 | 61.82 | 43.61 | 32.76 | 17.86 | |
| Book value per share | 4.98 | 59.44 | 46.97 | 32.83 | 18.8 | |
| Tangible book value per share | 6.54 | 59.44 | 46.97 | 32.83 | 18.8 | |
| Share holders equity per share | 4.98 | 59.44 | 46.97 | 32.83 | 18.8 | |
| Interest debt per share | 0 | 12.06 | 3.34 | 1.58 | 1.67 | |
| Market cap | 894.68M | 120.65M | 225.62M | 20.2M | 18.97M | |
| Enterprise value | 865.58M | 95.27M | 200.32M | 1.12M | -13.69M | |
| P/E ratio | -36.72 | -3.7 | -4.3 | -0.73 | -0.44 | |
| Price to sales ratio | 0 | 0 | 0 | 1.62 | 0 | |
| POCF ratio | -42.49 | -4.15 | -4.62 | -0.46 | -0.47 | |
| PFCF ratio | -39.55 | -4.03 | -4.51 | -0.45 | -0.47 | |
| P/B Ratio | 30.45 | 2.55 | 2.06 | 0.27 | 0.5 | |
| PTB ratio | 30.45 | 2.55 | 2.06 | 0.27 | 0.5 | |
| EV to sales | 0 | 0 | 0 | 0.09 | 0 | |
| Enterprise value over EBITDA | -37.93 | -3.09 | -3.68 | -0.03 | 0.3 | |
| EV to operating cash flow | -41.11 | -3.27 | -4.1 | -0.03 | 0.34 | |
| EV to free cash flow | -38.27 | -3.18 | -4 | -0.02 | 0.34 | |
| Earnings yield | -0.03 | -0.27 | -0.23 | -1.37 | -2.27 | |
| Free cash flow yield | -0.03 | -0.25 | -0.22 | -2.22 | -2.15 | |
| Debt to equity | 0 | 0.2 | 0.07 | 0.07 | 0.09 | |
| Debt to assets | 0 | 0.15 | 0.06 | 0.06 | 0.07 | |
| Net debt to EBITDA | 1.28 | 0.82 | 0.47 | 0.43 | 0.71 | |
| Current ratio | 7.54 | 6.9 | 7.75 | 8.35 | 5.75 | |
| Interest coverage | 0 | 0 | 0 | 22.68 | 0 | |
| Income quality | 0.86 | 0.89 | 0.89 | 1.23 | 0.94 | |
| Dividend Yield | 0 | 0.4 | 0 | 0 | 0 | |
| Payout ratio | 0 | -1.48 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 0 | 0 | 1.59 | 0 | |
| Research and developement to revenue | 0 | 0 | 0 | 2.96 | 0 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0.07 | 0.03 | 0.03 | 0.02 | 0.01 | |
| Capex to revenue | 0 | 0 | 0 | -0.06 | 0 | |
| Capex to depreciation | -0.68 | -0.45 | -0.61 | -0.37 | -0.34 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0.36 | 0 | |
| Graham number | 21.51 | 234.19 | 154.14 | 93.97 | 94.98 | |
| ROIC | -0.85 | -0.49 | -0.42 | -0.39 | -1.02 | |
| Return on tangible assets | -0.57 | -0.53 | -0.38 | -0.31 | -0.93 | |
| Graham Net | 4.27 | 43.26 | 31.84 | 27.6 | 14.62 | |
| Working capital | 25.51M | 42.95M | 91.62M | 71.57M | 33.98M | |
| Tangible asset value | 38.59M | 47.29M | 109.7M | 76M | 37.94M | |
| Net current asset value | 25.51M | 35.46M | 77.72M | 67.87M | 32.99M | |
| Invested capital | 0 | 0.2 | 0.07 | 0.07 | 0.09 | |
| Average receivables | 0 | 0 | 0 | 989K | 2.07M | |
| Average payables | 0 | 1.37M | 2.25M | 1.69M | 591.5K | |
| Average inventory | 0 | 0 | 0 | 0 | 0 | |
| Days sales outstanding | 0 | 0 | 0 | 57.76 | 0 | |
| Days payables outstanding | 0 | 221.32 | 300.9 | 73.47 | 0 | |
| Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
| Receivables turnover | 0 | 0 | 0 | 6.32 | 0 | |
| Payables turnover | 0 | 1.65 | 1.21 | 4.97 | 0 | |
| Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
| ROE | -0.83 | -0.69 | -0.48 | -0.36 | -1.13 | |
| Capex per share | -0.26 | -1.1 | -0.54 | -0.31 | -0.2 |
Quarterly Fundamentals Overview
Last date of statement is 2023-09-30 for Q3
| Metric | History | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0 | 6.23 | 0 | 0 | 0 | |
| Net income per share | -0.37 | 3.65 | -7.97 | -4.68 | -5.14 | |
| Operating cash flow per share | -0.4 | -0.1 | -7.09 | -4.36 | -4.98 | |
| Free cash flow per share | -0.41 | -0.18 | -7.25 | -4.41 | -4.98 | |
| Cash per share | 2.24 | 37.81 | 30.9 | 26.63 | 21.36 | |
| Book value per share | 2.22 | 37.89 | 31.55 | 27.46 | 22.39 | |
| Tangible book value per share | 2.22 | 37.89 | 31.55 | 27.46 | 22.39 | |
| Share holders equity per share | 2.22 | 37.89 | 31.55 | 27.46 | 22.39 | |
| Interest debt per share | 0.16 | 5.89 | 2.39 | 2.26 | 1.95 | |
| Market cap | 1.06B | 17.51M | 18.04M | 16.54M | 14.94M | |
| Enterprise value | 1.04B | -1.58M | -4.69M | -15.43M | -15.07M | |
| P/E ratio | -20.21 | 0.6 | -0.28 | -0.44 | -0.36 | |
| Price to sales ratio | 0 | 1.4 | 0 | 0 | 0 | |
| POCF ratio | -74.86 | -85.41 | -1.27 | -1.89 | -1.47 | |
| PFCF ratio | -74.1 | -49.6 | -1.25 | -1.87 | -1.47 | |
| P/B Ratio | 13.67 | 0.23 | 0.29 | 0.3 | 0.33 | |
| PTB ratio | 13.67 | 0.23 | 0.29 | 0.3 | 0.33 | |
| EV to sales | 0 | -0.13 | 0 | 0 | 0 | |
| Enterprise value over EBITDA | -76.45 | 0.73 | 0.39 | 1.58 | 1.96 | |
| EV to operating cash flow | -73.49 | 7.71 | 0.33 | 1.76 | 1.49 | |
| EV to free cash flow | -72.75 | 4.48 | 0.32 | 1.75 | 1.49 | |
| Earnings yield | -0.01 | 0.42 | -0.88 | -0.57 | -0.7 | |
| Free cash flow yield | -0.01 | -0.02 | -0.8 | -0.53 | -0.68 | |
| Debt to equity | 0.08 | 0.07 | 0.08 | 0.08 | 0.09 | |
| Debt to assets | 0.07 | 0.06 | 0.07 | 0.07 | 0.07 | |
| Net debt to EBITDA | 1.43 | 8.8 | 1.87 | 3.27 | 3.9 | |
| Current ratio | 9.56 | 8.35 | 8.61 | 8.93 | 7.25 | |
| Interest coverage | 28.95 | -0.35 | 49.46 | 0 | 0 | |
| Income quality | 1.06 | 0.26 | 0.99 | 0.93 | 0.97 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 0.42 | 0 | 0 | 0 | |
| Research and developement to revenue | 0 | 0.75 | 0 | 0 | 0 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0.01 | 0.72 | 0.02 | 0.01 | 0 | |
| Capex to revenue | 0 | -0.01 | 0 | 0 | 0 | |
| Capex to depreciation | -0.31 | -0.31 | -0.65 | -0.17 | 0 | |
| Stock based compensation to revenue | 0 | 0.12 | 0 | 0 | 0 | |
| Graham number | 4.32 | 55.75 | 75.24 | 53.79 | 50.88 | |
| ROIC | -0.15 | 0.23 | -0.22 | -0.15 | -0.23 | |
| Return on tangible assets | -0.14 | 0.08 | -0.21 | -0.15 | -0.19 | |
| Graham Net | 1.9 | 31.85 | 26.06 | 22.91 | 17.94 | |
| Working capital | 74.07M | 71.57M | 59.25M | 51.13M | 41.69M | |
| Tangible asset value | 77.49M | 76M | 63.04M | 55.06M | 45.53M | |
| Net current asset value | 68.78M | 67.87M | 55.87M | 48.64M | 39.92M | |
| Invested capital | 0.08 | 0.07 | 0.08 | 0.08 | 0.09 | |
| Average receivables | 83.5K | 1.07M | 1.98M | 1.98M | 1.98M | |
| Average payables | 390K | 510K | 414.5K | 178.5K | 236.5K | |
| Average inventory | 1.69M | 1.69M | 0 | 0 | 0 | |
| Days sales outstanding | 0 | 14.24 | 0 | 0 | 0 | |
| Days payables outstanding | 43.5 | 77.11 | 19.66 | 20.74 | 53.48 | |
| Days of inventory on hand | 405.78 | 0 | 0 | 0 | 0 | |
| Receivables turnover | 0 | 6.32 | 0 | 0 | 0 | |
| Payables turnover | 2.07 | 1.17 | 4.58 | 4.34 | 1.68 | |
| Inventory turnover | 0.22 | 0 | 0 | 0 | 0 | |
| ROE | -0.17 | 0.1 | -0.25 | -0.17 | -0.23 | |
| Capex per share | 0 | -0.07 | -0.16 | -0.04 | 0 |
SRZNW Frequently Asked Questions
What is Surrozen, Inc. stock symbol ?
Surrozen, Inc. is a US stock , located in South san francisco of Ca and trading under the symbol SRZNW
What is Surrozen, Inc. stock quote today ?
Surrozen, Inc. stock price is $0.029 today.
Is Surrozen, Inc. stock public?
Yes, Surrozen, Inc. is a publicly traded company.
Company Profile
- Market Capitalization 22.44M
- Employee 74
- CEO Mr. Craig C. Parker M.B.A.
- Headquarters South San Francisco,CA,US
- IPO Date 2021-08-10
-
Website
http://www.surrozen.com 
Surrozen, Inc., a biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair and regeneration. It is developing tissue-specific antibodies to engage the body's existing biological repair mechanisms with potential application across various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. Its products in pipeline include SZN-043 that stimulates hepatocyte regeneration, improves liver function, and reduces fibrosis; and SZN-1326, a bi-specific full-length human antibody that directly modulates Wnt signaling in target tissue by binding to particular Frizzled and LRP receptors that are highly expressed in intestinal crypts. The company was founded in 2016 and is headquartered in South San Francisco, California.
